Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
Transcript (slightly modified)
Should providers be involved in the development process of new reimbursement models?
I’m a crusader almost for the quadruple aim. Mostly everybody within healthcare, research, and healthcare policy understands the triple aim. The quadruple aim is additive to all the benefits of the triple aim. Quadruple aim, though, says exactly what your question implies: that we need to be including front-line caregivers when we’re designing these quality initiatives, whether it’s a CMS initiative, whether it’s a hospital initiative, or if you have a progressive group. If it’s an office-based quality improvement initiative, it’ll work umpteen times better if you include the front-line caregivers as early as you can in the design phase.
So, we’re doing that in Oklahoma. The 5 oncology practices that are part of OCM, we have brought together and we’re trying to make our own collaborative design for patients under 65 in Oklahoma, so we’ll see if it works. But, that’s precisely what we should be doing. Including the caregivers early on does 2 things: it increases the chance that the initiative will be successful, and it works against caregiver burnout, whether it’s a nurse or a doctor, pharmacist, or administrator, or lay caregivers who take care of our patients at home. We are all subject to burnout, and having caregivers as part of the design team lowers that risk.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More